Sweden's Peptonic Medical Q1 operating loss narrows on restructuring

Peptonic Medical AB

27/05/2026 07:40

Overview
Sweden medical technology firm's Q1 sales declined yr/yr, gross margin improved to 68%
Q1 operating loss narrowed compared to prior year after restructuring and cost cuts
Company launched two new VagiVital intimate care products after quarter end

Outlook
Company did not provide specific quantitative guidance for the current or full year

Result Drivers
COST REDUCTION - Co said extensive restructuring and cost-cutting measures improved cost-effectiveness and scalability
NORWEGIAN MARKET GROWTH - Co said Norwegian consumer market grew from low levels to a significant part of e-commerce sales
PARTNER SALES VARIABILITY - Co said partner sales remain uneven between quarters due to periodic large orders and deliveries

Company press release: ID:nWkr22nG26

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
 
SEK 3.14 mln
 
Q1 EPS
 
-SEK 0.0005
 
Q1 Gross Margin
 
68%
 
Q1 Gross Profit
 
SEK 2.12 mln
 
Q1 Operating Profit
 
-SEK 5.33 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)